Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,664 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: Shock
Interventions: Ascorbic Acid, Ringers Lactate or Normal Saline; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Arthritis, Juvenile Rheumatoid
Interventions: Celecoxib, Naproxen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 31
States / cities: San Diego, California • Hartford, Connecticut • Delray Beach, Florida + 21 more

Conditions: Ischemia-Reperfusion Injury, Kidney Diseases
Interventions: Reparixin continuous infusion, reparixin intermittent infusion, placebo infusion; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Philadelphia, Pennsylvania

Conditions: Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: ELU001; Drug
Lead sponsor: Elucida Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 18
States / cities: Phoenix, Arizona • Fullerton, California • Jacksonville, Florida + 15 more

Conditions: Seborrheic Keratosis
Interventions: A-101 Vehicle, A-101 (40) Topical Solution, A-101 (32.5) Topical Solution; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 5
States / cities: Snellville, Georgia • Clinton Township, Michigan • Portland, Oregon + 2 more

Conditions: Healthy
Interventions: Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 25 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bioequivalence
Interventions: Tacrolimus; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions: Laromustine (VNP40101M) and Ara-C; Drug
Lead sponsor: Viron Therapeutics Inc; Industry
Eligibility: 60 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Coronary Syndrome, Depressive Symptoms
Interventions: Cognitive Behavioral Therapy (CBT), Antidepressant Medication, Standard Care, Depressive symptom screener, No intervention; Other · Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older
Enrollment: 1,501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Bloomington, Minnesota • New York, New York • Henderson, North Carolina + 1 more

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions: ENS-002; Biological
Lead sponsor: Concerto Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Hollywood, Florida • Beverly, Massachusetts • Austin, Texas

Conditions: Acquired Immune Deficiency Syndrome
Interventions: Lopinavir 400 mg/ritonavir 100 mg, Efavirenz; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Chicago, Illinois

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more

Conditions: High Risk Prostate Carcinoma, Prostate Cancer
Interventions: Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C), Magnetic Resonance Imaging (MRI), Non-investigational radical prostatectomy (RP), Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT); Drug · Procedure
Lead sponsor: Ivan de Kouchkovsky, MD; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Reduction of Small Intestinal Ulceration Risk
Interventions: Bif195, Placebo; Dietary Supplement
Lead sponsor: Chr Hansen; Industry
Eligibility: 40 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Interventions: Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy; Drug · Procedure
Lead sponsor: Persephone Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: Orange, California • San Diego, California • Miami, Florida + 6 more

Conditions: IgA Nephropathy (IgAN)
Interventions: Avacopan, Prednisone, Methylprednisolone (drug), Prednisolone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Autoimmune Epilepsy
Interventions: Intravenous Immunoglobulin, Placebos, Normal Saline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Opioid Consumption, Postoperative
Interventions: Suzetrigine, Standard Care (in control arm); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, Polatuzumab vedotin, Rescue Medication; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 74
States / cities: Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 65 more

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: Nivolumab, Cisplatin, Cetuximab, IMRT; Drug · Radiation
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 11
States / cities: Palo Alto, California • Orlando, Florida • Atlanta, Georgia + 8 more

Conditions: Leber Hereditary Optic Neuropathy (LHON)
Interventions: NR082 Injection, Injection needle; Drug · Device
Lead sponsor: Neurophth Therapeutics Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Palo Alto, California • Aurora, Colorado • Philadelphia, Pennsylvania

Conditions: HIV, AIDS
Interventions: Kaletra (drug); Drug
Lead sponsor: Lampiris, Harry W., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Dental Pain
Interventions: Full Dose Strength, Quarter dose strength, Half dose strength, Acetaminophen standard dose, Ibuprofen low dose, Ibuprofen high dose, Placebo; Drug
Lead sponsor: AFT Pharmaceuticals, Ltd.; Industry
Eligibility: 16 Years to 40 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

High Dose Vitamin C in the Critically Ill Patient

A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA

Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes

Topical ENS-002 for Atopic Dermatitis in Adults

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Safety and Efficacy of a Drug Delivery System in Glaucoma

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

The Effect of a Probiotic Strain on Aspirin-induced GI Damage

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease

Maxi-Analgesic Phase 2 Study to Compare the Analgesic Effects in Different Dosing Groups to Treat Teeth Extraction Pain